Navigation Links
KemPharm Completes Successful End-of-Phase 2 Meeting with FDA
Date:11/1/2013

NORTH LIBERTY, Iowa, Nov. 1, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration (FDA) for its lead pain candidate, KP201 (benzhydrocodone hydrochloride and acetaminophen).  Based on the results of the meeting, KemPharm believes the completed and ongoing clinical, non-clinical and CMC development programs will allow for the submission of a New Drug Application (NDA) for KP201 in the third quarter of 2014.

During the meeting, representatives from the FDA reviewed KemPharm's current portfolio of data for KP201, including the recently completed bioequivalence and "steady-state" pivotal clinical studies.  It was determined that the final data package, as proposed by KemPharm, would support a potential 505(b)(2) filing pathway without any additional efficacy, toxicology or safety data being required.

Travis C. Mickle, Ph.D., President and CEO of KemPharm, commented, "The positive feedback we received from the Agency re-affirms prior discussions related to our clinical and non-clinical program for KP201 and our plan to pursue an NDA via the 505(b)(2) pathway. Based on their advice, we are extremely confident in our plan to submit an NDA by the third quarter of 2014 and seek potential approval of the first novel pain therapy of the morphine class to be developed in a number of years with an officially recognized new chemical structure."

KP201 is in development for the treatment of acute moderate to moderately severe pain. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induce
'/>"/>

SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
2. KemPharms KP201 Featured at the International Conference on Opioids
3. Micropharma completes development of first microbiome clinical lab test using digital PCR technology
4. Syneron Medical Completes and Summarizes the Multi-site Clinical Study Agreed Upon with FDA for the UltraShape Contour I
5. AIS (American Internet Services) Completes Audit for Title 21 CFR Part 11 Compliance
6. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
7. VIVEX BIOMEDICAL Successfully Completes $7.6 Million Round of Financing
8. Boston Scientific Completes $1.05 Billion Senior Notes Offering
9. SureClinical Completes FDA 21 CFR Part 11 Compliance Audit of SureTrial® eTMF Cloud Edition
10. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
11. Oligomerix, Inc. Completes Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... La Jolla, CA (PRWEB) July 23, 2014 ... adipose stem cell therapy in the US aimed at ... today announced their newest clinical study for Parkinson’s disease. ... and efficacy of stem cell therapy are paramount when ... , This clinical study makes stem cell therapy accessible ...
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 DuPont Pioneer ... business as vice president of Agricultural Biotechnology (ABT), effective ... where he served most recently as president, chief executive ... and business leadership in the seed and crop protection ... Paul E. Schickler , president of DuPont Pioneer. ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber ... biotechnology company producing sustainable chemicals, today announced that the ... full their option to purchase an additional 420,000 ... price of $12.00 per share, less underwriting discounts ... underwritten public offering of 2,800,000 shares of common ...
Breaking Biology Technology:StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3
... 4, 2008, SAN DIEGO, Oct. 27 Neurocrine ... Gorman, President and Chief,Executive Officer of Neurocrine Biosciences will ... New York., The live presentation takes place Tuesday, ... a.m. Pacific Time (PT). The presentation will,be simultaneously webcast ...
... BioTrends Research Group, Inc. was,named one of ... Philadelphia region by the Philadelphia 100(R), a joint ... Entrepreneurs, Forum of,Greater Philadelphia, and the Philadelphia Business ... "This recognition is a testament to the ...
... Osteotech, Inc.,(Nasdaq: OSTE ) announced today ... financial results will be released Friday, November 7,2008. ... Owusu-Akyaw, President and,Chief Executive Officer, as well as ... 2008, at 9:00 a.m. Eastern time. You are ...
Cached Biology Technology:Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference 2
(Date:7/22/2014)... spot with natural tourism resources, a recent study revealed a ... Geoscience and Mineral Resources (KIGAM) indicated that there are the ... 5,000 years ago. That is the first time to actually ... volcano 5,000 years ago in the inland part of the ... The research team led by Dr. Jin-Young Lee confirmed in ...
(Date:7/22/2014)... The darker side of meerkats which sees them prevent ... explained in a new study. , Research into the desert ... pair and many adult helpers shows that the alpha ... breed. , The study shows how this way of life, ... can prove effective despite its sinister side. , Dominant ...
(Date:7/22/2014)... July 22, 2014, Cleveland: A type of immune ... diseases, such as Alzheimer,s disease and multiple sclerosis ... brain injury (TBI) and may slow the progression ... published today in the online journal Nature ... Bruce Trapp, PhD, Chair of the Department of ...
Breaking Biology News(10 mins):Jeju Island is a live volcano 2Cleveland Clinic researchers discover neuroprotective role of immune cell 2
... of North Africa,s major droughts of centuries past, reveals ... year 1179. The first multi-century drought reconstruction that ... droughts during the 13th and 16th centuries and the ... international research team figured out northwest Africa,s climate history ...
... University of Rochester Medical Center scientists discovered a defect ... earliest stages of abnormal skull development in newborns, known as ... pathways set off a cascade of events that regulate bone ... published May 25, 2010, in the journal Science Signaling ...
... Association today launched a first-of-its-kind educational tool to ... college and university professors provide evidence to support ... academic world is commonly predicated on judging a ... Sally T. Hillsman, ASA,s Executive Officer. "While teaching ...
Cached Biology News:20th century one of driest in 9 centuries for northwest Africa 220th century one of driest in 9 centuries for northwest Africa 3Stem-cell disruption induces skull deformity, UR study shows 2American Sociological Association launches first-of-its-kind teaching tool 2American Sociological Association launches first-of-its-kind teaching tool 3
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... Mouse Antibody to Human Cytokeratin TYPE ... Basic (Type II) keratins. Including epidermal cell ... at 58kD, 65kD and 67kD. Broad keratin ... oesophagus and cornea. Immunogen: ...
BD BioCoat Fibronectin 150 mm Culture Dishes...
Biology Products: